Amgen sells Takeda Japanese rights to 13 drugs in a deal that could be worth up to $1.2B
US biotechnology major Amgen has entered a broad alliance to develop and commercialize up to 13 molecules in Japan with leading local drugmaker Takeda.
The financial terms of the deal include an upfront cash payment to the US firm of $200.0 million, as well as up to $340.0 million in expected worldwide development costs over the next few years, $362.0 million in success-based milestone payments and double-digit royalties on sales of the drugs in Japan.
In addition, Takeda plans to acquire all the shares of Amgen's local subsidiary, Amgen KK. The US firm anticipates the transaction will close in the first quarter.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze